News and Press Releases

Tiziana Life Sciences Announces Johns Hopkins University Commences Dosing Nasal Foralumab in Phase 2 Multiple Sclerosis Clinical Trial

2 April 2025 -- New York, US -- Tiziana Life Sciences, Ltd, a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3...

Category: Biotechnology, Clinical Trials, Drug Discovery, Pharmaceutical
Posted: April 2, 2025

Tiziana Life Sciences 14/15 Conduit Street London W1S 2XJ United Kingdom

AC Immune Reports Further Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson’s Disease

Active immunotherapy with ACI-7104.056 induces high anti-a-synuclein (a-syn) antibody levels on average over 20-fold higher than placebo after 4 immunizations Repeated immunizations amplify the anti-a-syn antibody response, supporting boostability and...

Category: Biotechnology, Clinical Trials, Other, Pharmaceutical
Posted: April 2, 2025

EPFL Innovation Park-Building B 1015 Lausanne / Switzerland

Bend Bioscience Adds Commercial Spray Drying & Granulation in Georgia

2 April 2025 – Clearwater, Florida, US – Bend Bioscience, a leading innovation, science, and pharmaceutical services partner, today announced the addition of a commercial-scale spray dryer and a Gerteis...

Category: Drug Delivery
Posted: April 2, 2025

SHL Medical opens new US$220 million manufacturing facility in the US to serve growing autoinjector market

1 April 2025 – SHL Medical, a global leader in the design, development, and manufacturing of advanced self-injection solutions, has officially inaugurated its new state-of-the-art manufacturing facility in North Charleston,...

Category: Drug Delivery, Manufacturing and Packing
Posted: April 2, 2025

Gubelstrasse 22, 6300 Zug

NICE publishes guidance in England & Wales recommending Altuvoct (efanesoctocog alfa) as a treatment option for people with severe haemophilia A aged 2 years and over

2 April 2025 -- Stockholm, Sweden -- Sobi in the UK today announced that the National Institute for Health and Care Excellence (NICE) has issued its Final Guidance in England...

Category: Clinical Trials, Other, Pharmaceutical
Posted: April 2, 2025

Norra Stationsgatan 93A Stockholm

CSL Behring and GKV-Spitzenverband Agree on Reimbursement Price for HEMGENIX® – Europe’s First Gene Therapy for Haemophilia B

2 April 2025 -- Marburg, Germany -- CSL Behring and the GKV-Spitzenverband (National Association of Statutory Health Insurance Funds) have successfully concluded negotiations on the reimbursement price of HEMGENIX. This...

Category: Other, Pharmaceutical
Posted: April 2, 2025

CSL Global Headquarters, 655 Elizabeth Street, Melbourne VIC 3000 Australia

Phesi launches self-service Investigator Site Profiler solution to enhance precision of investigator site selection

Solution benefits clinical development and medical affairs groups – eliminating 20%-30% of investigator sites where there isn’t sufficient data to ensure performance 2 April 2025 -- Massachusetts, US -- Phesi,...

Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: April 2, 2025

East Lyme, Connecticut, US

Myonex Unveils Enhanced Services for a Simplified Experience

31 March 2025 – Horsham, PA, US – Myonex, a global leader in clinical trial supply and pharmaceutical commercial services, has announced new and expanded, integrated offerings to better address...

Category: Clinical Trials, Logistics, Pharmaceutical
Posted: April 1, 2025

100 Progress Dr., Horsham, PA 19044

Besins Healthcare UK launches Prometrium (progesterone) 400mg soft vaginal capsules

The first and only licensed treatment in the UK for the prevention of miscarriage in women with early pregnancy bleeding and a history of recurrent miscarriage 1 April 2025 --...

Category: Other, Pharmaceutical
Posted: April 1, 2025

Besins Healthcare Monaco S.A.M., Le Concorde, 11 rue du Gabian - 98000 MONACO

Navigo Proteins Announces Strategic R&D Collaboration with SCK CEN to Develop Targeted Radiotheranostics

1 April 2025 -- Halle, Germany and Mol, Belgium -- Navigo Proteins GmbH, a leader in precision medicine and next-generation radiotheranostics, today announced a strategic research collaboration with SCK CEN,...

Category: Biotechnology, Clinical Trials, Drug Discovery, Pharmaceutical
Posted: April 1, 2025

Heinrich-Damerow-Strasse 1 06120 Halle Germany

ChinaBio Partnering Forum 2025: Connecting China’s Biotech Innovations with the Global Life Science Ecosystem

1 April 2025 -- Shanghai, China -- ChinaBio® Partnering Forum, the largest and most productive life science partnering event in China, returns in 2025 with a hybrid format to facilitate...

Category: Biotechnology, Other, Pharmaceutical
Posted: April 1, 2025

Kerry Hotel Pudong, Shanghai No. 1388, Hua mu Road, Pudong, Shanghai, 201204 China

Domain Therapeutics to Present Data on its GPCR Lead Programs at AACR Annual Meeting 2025

Presentation of Phase I clinical results from DT-9081, an EP4 receptor antagonist, and preclinical data on DT-7012, a Treg depleting anti-CCR8 antibody Preclinical findings highlight immuno-oncology breakthrough properties for its...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: April 1, 2025

PARC D'INNOVATION 220 Boulevard Gonthier D'Andernach 67400 Strasbourg - Illkirch - France

OKYO Pharma Announces Positive Data in Long-Term Stability of Urcosimod

Urcosimod in Phase 2 clinical trial for Neuropathic Corneal Pain shown to have Long-Term Stability Urcosimod stable in single-use ampoules for more than 2½ years FDA requires drug to show...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 31, 2025

OKYO Pharma Floor 4, 14/15 Conduit St London W1S 2XJ

Novo Nordisk A/S: Rybelsus® (oral semaglutide 14mg) demonstrates superior reduction in cardiovascular events in the SOUL trial at ACC 2025

Rybelsus reduced major adverse cardiovascular events by 14% vs placebo in adults with type 2 diabetes and cardiovascular and/or chronic kidney disease in the SOUL cardiovascular outcomes trial Data were...

Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 29, 2025

Novo Nordisk A/S Novo Allé, 2880 Bagsvaerd Denmark

TREMFYA (guselkumab) receives positive CHMP opinion for treatment of patients with moderately to severely active Crohn’s Disease

Recommendation based on the findings from the Phase 3 studies (GALAXI programme and GRAVITI) in Crohn’s disease 28 March 2025 -- Beerse, Belgium -- Johnson & Johnson today announced that...

Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 28, 2025

Janssen-Cilag Limited 50-100 Holmers Farm Way High Wycombe Buckinghamshire HP12 4EG